2024-2025 COVID-19 vaccine recommendations
Everyone 6-months and older is recommended to get at an updated 2024–2025 COVID-19 vaccine to protect against the potentially serious outcomes of COVID-19 illness.
Updated 2024-2025 COVID-19 vaccines are now available.
For 2024-2025, FDA has approved and authorized two mRNA COVID-19 vaccines, (Moderna and Pfizer COVID-19 vaccines) and one protein subunit COVID-19 vaccine (Novavax COVID-19 vaccine).
View CDC recommendations for use of these vaccines in people ages 6 months and older:
- For patients: Staying Up to Date with COVID-19 Vaccines | CDC
- For health care providers: Use of COVID-19 Vaccines in the United States | CDC
Additional COVID-19 vaccine resources include:
Reporting of vaccine adverse events
Adverse events that occur in a recipient following COVID-19 vaccination should be reported to VAERS. Vaccination providers are required by FDA and the provider agreement for the CDC COVID-19 Vaccination Program to report the following that occur after any COVID-19 vaccination:
- Vaccine administration errors whether or not associated with an adverse event
- Serious adverse events, irrespective of attribution to vaccination
- Cases of Multisystem Inflammatory Syndrome (MIS) in adults and children
- Cases of myocarditis
- Cases of pericarditis
- Cases of COVID-19 that result in hospitalization or death
Reporting is encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused the event. Information on how to submit a report to VAERS is available at vaers.hhs.gov or by calling 1-800-822-7967.
Resources for healthcare professionals
Standing orders
Standing Order for Dispensing and Administration of COVID-19 vaccine: 2025-2026. The Department of Public Health has recently issued a standing order allowing for all qualified pharmacy personnel at Massachusetts pharmacies to dispense and administer COVID-19 vaccine in Massachusetts to all eligible persons.